دورية أكاديمية
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.
| العنوان: | Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. |
|---|---|
| المؤلفون: | Jiang Y; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.; These authors contributed equally to the first authorship., Meyers TJ; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.; These authors contributed equally to the first authorship., Emeka AA; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Cooley LF; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Cooper PR; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Lancki N; Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Helenowski I; Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Kachuri L; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA., Lin DW; Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, WA 98109, USA.; Department of Urology, University of Washington, Seattle 98195, WA, USA., Stanford JL; Fred Hutchinson Cancer Research Center, Cancer Epidemiology Program, Public Health Sciences, Seattle, WA 98109, USA.; Department of Epidemiology, University of Washington, School of Public Health, Seattle, WA 98195, USA., Newcomb LF; Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, WA 98109, USA.; Department of Urology, University of Washington, Seattle 98195, WA, USA., Kolb S; Fred Hutchinson Cancer Research Center, Cancer Epidemiology Program, Public Health Sciences, Seattle, WA 98109, USA.; Department of Epidemiology, University of Washington, School of Public Health, Seattle, WA 98195, USA., Finelli A; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Fleshner NE; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Komisarenko M; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Eastham JA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ehdaie B; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Benfante N; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Logothetis CJ; Departments of Genitourinary Medical Oncology and Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Gregg JR; Departments of Genitourinary Medical Oncology and Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Perez CA; Departments of Genitourinary Medical Oncology and Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Garza S; Departments of Genitourinary Medical Oncology and Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Kim J; Departments of Genitourinary Medical Oncology and Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Marks LS; Department of Urology, David Geffen School of Medicine at UCLA, USA., Delfin M; Department of Urology, David Geffen School of Medicine at UCLA, USA., Barsa D; Department of Urology, David Geffen School of Medicine at UCLA, USA., Vesprini D; Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, ON, Canada., Klotz LH; Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, ON, Canada., Loblaw A; Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, ON, Canada., Mamedov A; Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, ON, Canada., Goldenberg SL; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Higano CS; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Spillane M; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Wu E; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Carter HB; Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Pavlovich CP; Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Mamawala M; Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Landis T; Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Carroll PR; Department of Urology, University of California, San Francisco, San Francisco, CA, USA., Chan JM; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.; Department of Urology, University of California, San Francisco, San Francisco, CA, USA., Cooperberg MR; Department of Urology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Cowan JE; Department of Urology, University of California, San Francisco, San Francisco, CA, USA., Morgan TM; Department of Urology, University of Michigan, Ann Arbor, MI, USA., Siddiqui J; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Martin R; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Klein EA; Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, USA., Brittain K; Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, USA., Gotwald P; Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, USA., Barocas DA; Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA., Dallmer JR; Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Gordetsky JB; Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Steele P; Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA., Kundu SD; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Stockdale J; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Roobol MJ; Department of Urology, Erasmus Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Venderbos LDF; Department of Urology, Erasmus Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Sanda MG; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Arnold R; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Patil D; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Evans CP; Department of Urologic Surgery, University of California, Davis Medical Center, Sacramento, CA, USA., Dall'Era MA; Department of Urologic Surgery, University of California, Davis Medical Center, Sacramento, CA, USA., Vij A; Department of Urologic Surgery, University of California, Davis Medical Center, Sacramento, CA, USA., Costello AJ; Department of Urology, Royal Melbourne Hospital and University of Melbourne, Australia., Chow K; Department of Urology, Royal Melbourne Hospital and University of Melbourne, Australia., Corcoran NM; Department of Urology, Royal Melbourne Hospital and University of Melbourne, Australia., Rais-Bahrami S; Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.; Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA., Phares C; Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA., Scherr DS; Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA., Flynn T; Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA., Karnes RJ; Mayo Clinic Department of Urology, Rochester, MN, USA., Koch M; Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA., Dhondt CR; Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA., Nelson JB; Department of Urology, University of Pittsburgh School of Medicine, PA, USA., McBride D; Department of Urology, University of Pittsburgh School of Medicine, PA, USA., Cookson MS; Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Stratton KL; Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Farriester S; Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Hemken E; Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Stadler WM; University of Chicago Comprehensive Cancer Center, Chicago, IL, USA., Pera T; University of Chicago Comprehensive Cancer Center, Chicago, IL, USA., Banionyte D; University of Chicago Comprehensive Cancer Center, Chicago, IL, USA., Bianco FJ Jr; Urological Research Network, Miami Lakes, FL, USA., Lopez IH; Urological Research Network, Miami Lakes, FL, USA., Loeb S; Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, NY, USA., Taneja SS; Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, NY, USA., Byrne N; Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, NY, USA., Amling CL; Department of Urology, Oregon Health and Science University, Portland, OR, USA., Martinez A; Department of Urology, Oregon Health and Science University, Portland, OR, USA., Boileau L; Department of Urology, Oregon Health and Science University, Portland, OR, USA., Gaylis FD; Genesis Healthcare Partners, Department of Urology, University of California, San Diego, CA, USA., Petkewicz J; Division of Urology, NorthShore University Health System, Evanston, IL, USA., Kirwen N; Division of Urology, NorthShore University Health System, Evanston, IL, USA., Helfand BT; Division of Urology, NorthShore University Health System, Evanston, IL, USA., Xu J; Division of Urology, NorthShore University Health System, Evanston, IL, USA., Scholtens DM; Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Catalona WJ; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.; These authors contributed equally to the senior authorship., Witte JS; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.; Department of Urology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Departments of Epidemiology and Population Health, Biomedical Data Science, and Genetics, Stanford University, Stanford, CA, USA.; These authors contributed equally to the senior authorship. |
| المصدر: | HGG advances [HGG Adv] 2022 Jan 13; Vol. 3 (1). Date of Electronic Publication: 2021 Nov 19. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101772885 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-2477 (Electronic) Linking ISSN: 26662477 NLM ISO Abbreviation: HGG Adv Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: New York : Elsevier Inc., [2020]- |
| مستخلص: | Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of which were not previously associated with PC risk. With a transcriptome-wide association study (TWAS), we found two genes associated with conversion ( MAST3 , p = 6.9×10 -7 and GAB2 , p = 2.0×10 -6 ). Moreover, increasing values of a previously validated 269-variant genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS-or the intensity of monitoring on AS- versus treatment for the initial management of patients with low-risk PC. Competing Interests: Declaration of Interests The authors declare no competing interests. |
| References: | J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686) Prostate. 2008 Apr 1;68(5):489-97. (PMID: 18213635) Mol Oncol. 2020 Jan;14(1):129-138. (PMID: 31736271) Nat Genet. 2021 Jan;53(1):65-75. (PMID: 33398198) Prostate. 2012 Feb 1;72(2):147-56. (PMID: 21538423) Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2136-40. (PMID: 20080650) Prostate. 2020 Nov;80(15):1314-1321. (PMID: 33258481) Mol Med Rep. 2016 Oct;14(4):3357-61. (PMID: 27511603) Urol Clin North Am. 2021 Aug;48(3):401-409. (PMID: 34210494) J Natl Compr Canc Netw. 2020 Nov 02;18(11):1492-1499. (PMID: 33152695) Cell Rep. 2015 Dec 22;13(11):2345-2352. (PMID: 26686625) Eur J Surg Oncol. 2009 May;35(5):527-31. (PMID: 19004604) Urology. 2020 Apr;138:91-97. (PMID: 31899230) Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1196-203. (PMID: 21467234) Prostate. 2021 Jul;81(10):703-709. (PMID: 33956350) PLoS Genet. 2017 Jul 17;13(7):e1006916. (PMID: 28715421) Diagn Pathol. 2016 Mar 09;11:25. (PMID: 26956509) Hum Mol Genet. 2013 Jan 15;22(2):408-15. (PMID: 23065704) Cancer Res. 2006 Oct 1;66(19):9445-52. (PMID: 17018599) Bioinformatics. 2019 Jun 1;35(11):1968-1970. (PMID: 30395168) Prostate. 2010 Dec 1;70(16):1729-38. (PMID: 20564319) Eur Urol. 2019 May;75(5):846-852. (PMID: 30528221) Prostate. 2017 Mar;77(4):425-434. (PMID: 27900799) Prostate. 2013 Jan;73(1):11-22. (PMID: 22549899) Prostate. 2014 Jan;74(1):1-9. (PMID: 24037755) Int J Cancer. 2012 Feb 15;130(4):876-84. (PMID: 21445969) Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. (PMID: 23535732) JAMA. 2018 Jun 5;319(21):2231-2233. (PMID: 29800017) Genes Dev. 1999 Nov 15;13(22):2983-95. (PMID: 10580005) Nat Commun. 2018 Nov 8;9(1):4568. (PMID: 30410027) Am J Hum Genet. 2019 Jan 3;104(1):65-75. (PMID: 30595370) Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1599-610. (PMID: 21715604) Clin Cancer Res. 2011 Mar 1;17(5):1075-81. (PMID: 21343373) Cancer Res. 2007 Nov 15;67(22):10642-6. (PMID: 18006803) N Engl J Med. 2000 Jul 13;343(2):78-85. (PMID: 10891514) Prostate. 2010 Apr 1;70(5):502-7. (PMID: 19908238) Breast Cancer Res. 2017 Jun 19;19(1):72. (PMID: 28629464) Biochim Biophys Acta. 1999 Jan 29;1423(1):F1-13. (PMID: 9989206) Sci Transl Med. 2010 Dec 15;2(62):62ra92. (PMID: 21160077) Nat Genet. 2008 Mar;40(3):281-3. (PMID: 18264098) J Urol. 2008 Jun;179(6):2197-201; discussion 2202. (PMID: 18423739) Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1928-36. (PMID: 21846818) Asian J Androl. 2016 Jul-Aug;18(4):509-14. (PMID: 27297129) N Engl J Med. 2016 Oct 13;375(15):1415-1424. (PMID: 27626136) Cancer Prev Res (Phila). 2011 May;4(5):719-28. (PMID: 21367958) Stat Med. 2006 Oct 30;25(20):3474-86. (PMID: 16220486) Oncol Lett. 2020 Oct;20(4):99. (PMID: 32831918) Prostate Cancer Prostatic Dis. 2021 Sep;24(3):845-851. (PMID: 33723363) J Urol. 2015 Mar;193(3):807-11. (PMID: 25261803) Genes Immun. 2008 Oct;9(7):602-12. (PMID: 18650832) Bioinformatics. 2010 Sep 1;26(17):2190-1. (PMID: 20616382) JAMA Oncol. 2020 Oct 1;6(10):e203187. (PMID: 32852532) Mt Sinai J Med. 2010 Nov-Dec;77(6):643-54. (PMID: 21105126) Prostate. 2006 Dec 1;66(16):1729-43. (PMID: 16998812) Recent Results Cancer Res. 2014;202:9-26. (PMID: 24531773) J Urol. 2021 Nov;206(5):1157-1165. (PMID: 34181465) J Clin Oncol. 2020 May 1;38(13):1474-1494. (PMID: 31829902) Prostate. 2016 Sep;76(12):1120-9. (PMID: 27197965) PLoS Genet. 2019 Jan 22;15(1):e1007889. (PMID: 30668570) Nat Genet. 2008 Mar;40(3):316-21. (PMID: 18264097) J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660) Eur Urol. 2018 Aug;74(2):211-217. (PMID: 29433975) Prostate. 2011 Mar 1;71(4):394-402. (PMID: 20860009) PLoS One. 2014 Apr 16;9(4):e93436. (PMID: 24740154) Prostate. 2013 Nov;73(15):1623-35. (PMID: 24038036) Eur Urol. 2019 Mar;75(3):523-531. (PMID: 30385049) J Urol. 2021 Nov;206(5):1147-1156. (PMID: 34503355) J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. (PMID: 31085757) Genome Res. 2009 Sep;19(9):1655-64. (PMID: 19648217) J Urol. 2009 Jul;182(1):101-4; discussion 105. (PMID: 19450841) Nat Commun. 2017 Jan 31;8:14248. (PMID: 28139693) Prostate. 2009 Oct 1;69(14):1548-56. (PMID: 19562729) Int J Cancer. 2020 Nov 15;147(10):2735-2742. (PMID: 32399975) Nat Genet. 2018 Jul;50(7):928-936. (PMID: 29892016) JAMA Oncol. 2017 Oct 1;3(10):1393-1398. (PMID: 27768168) Front Biosci. 2007 May 01;12:4101-10. (PMID: 17485361) JAMA Netw Open. 2020 Sep 1;3(9):e2018318. (PMID: 32986109) J Clin Oncol. 2015 Jan 20;33(3):272-7. (PMID: 25512465) Mol Cancer Res. 2017 Nov;15(11):1469-1480. (PMID: 28811363) Oncotarget. 2016 Nov 15;7(46):76140-76150. (PMID: 27764811) JAMA Netw Open. 2020 Dec 1;3(12):e2031349. (PMID: 33369661) Carcinogenesis. 2016 Jan;37(1):63-71. (PMID: 26586793) JAMA. 2018 Dec 25;320(24):2553-2563. (PMID: 30575882) |
| معلومات مُعتمدة: | P50 CA180995 United States CA NCI NIH HHS; P50 CA097186 United States CA NCI NIH HHS; R01 CA158627 United States CA NCI NIH HHS; U01 CA224255 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; K05 CA175147 United States CA NCI NIH HHS; U01 CA113913 United States CA NCI NIH HHS; P50 CA186786 United States CA NCI NIH HHS; HHSN268201700006C United States HL NHLBI NIH HHS; R01 CA195505 United States CA NCI NIH HHS; UL1 TR000445 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: genetics; genome-wide association study; prostate; prostatic neoplasms |
| تواريخ الأحداث: | Date Created: 20220107 Latest Revision: 20240211 |
| رمز التحديث: | 20240211 |
| مُعرف محوري في PubMed: | PMC8725988 |
| DOI: | 10.1016/j.xhgg.2021.100070 |
| PMID: | 34993496 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2666-2477 |
|---|---|
| DOI: | 10.1016/j.xhgg.2021.100070 |